Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Management of Osilodrostat Therapy in Patients With Cushing's Syndrome: A Modified Delphi Consensus Panel
Samson, Susan L. , Donegan, Diane , Geer, Eliza B. , Gordon, Murray B. , Huang, Wenyu , Ioachimescu, Adriana G. , Silverstein, Julie , Yuen, Kevin C.J. , Huang, Wenyu , Ioachimescu, Adriana G , Yuen, Kevin C J , Hamidi, Oksana , Spencer-Segal, Joanna L. , Tritos, Nicholas A.

Journal of the Endocrine Society | June 27, 2025 | Volume: 9 | Issue: 8 | Pages: No page available

10.1210/jendso/bvaf103 | PMID 40620482 Get It

Abstract Introduction Endogenous Cushing's syndrome (CS) is a rare endocrine disorder that chronically exposes patients to supraphysiological cortisol levels. Primary therapy for CS consists of surgery. Medical therapies are also considered for many patients with CS, including those who are not surgical candidates or have persistent or recurrent hypercortisolism after surgery. Osilodrostat, an adrenal steroidogenesis inhibitor, demonstrated sustained efficacy and safety in phase 3 clinical trials and is currently approved to treat endogenous CS in Europe and the United States. Because of limited clinical experience, questions remain about how to individualize osilodrostat treatment for different clinical scenarios and special populations. Additional guidance from experts based on clinical study and real-world experiences with osilodrostat is needed. Methods A modified Delphi consensus panel study was conducted consisting of 13 specialists from high-volume endocrinology centers with experience prescribing osilodrostat. Advisors participated in 3 consensus rounds (2 anonymous surveys, 1 virtual workshop) over approximately 10 months to provide guidance and recommendations on optimal osilodrostat use. Results Over 2 surveys and a 2-hour virtual workshop, 26 statements related to osilodrostat achieved consensus among Delphi panelists and 5 were excluded. Topics included patient preparation before osilodrostat initiation, baseline testing, dosing at onset and during treatment, managing dose adjustments, monitoring during dose titration, and treatment alterations for planned and unexpected clinical events. Conclusion Treatment guidance and recommendations for osilodrostat use were obtained using the Delphi method. These statements are intended to provide physicians with education and guidance on using osilodrostat to optimally treat patients with CS.
Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration
Damianos, John , Bledsoe, Adam C. , Camilleri, Michael , Murray, Joseph A. , Bledsoe, Adam C , Murray, J A , Damianos, John A

Gut | June 27, 2025 | Volume: 75 | Issue: 4 | Pages: 826-838

10.1136/gutjnl-2025-335373 | PMID 40579122 Get It

Coeliac disease is characterised by immune-mediated damage to the small intestine in response to dietary gluten in genetically predisposed individuals. Increased intestinal permeability is a central component to its pathophysiology. This review explores the evidence for increased permeability in coeliac disease and the underlying mechanisms, including the roles of zonulin, inflammatory cytokines, microbial alterations and immune responses to gliadin peptides. We also review comprehensively the therapies targeting barrier integrity and normalising intestinal permeability, including particular diets and supplements, and experimental and improved medications including larazotide acetate and IMU-856. Finally, we highlight the need for reliable biomarkers for evaluating increased permeability in coeliac disease and advocate for further research on therapies which normalise barrier function, particularly as a strategy to maintain remission.
A shot to the gut: appendicitis triggered by retained buckshot
Kaoukabani, Georges , Shariq, Omair A. , Zietlow, John , Shariq, Omair, Zietlow, John M, Alva‐Ruiz, Roberto , Carroll, Joseph T.

Journal of Surgical Case Reports | June 27, 2025 | Volume: 2025 | Issue: 6 | Pages: No page available

10.1093/jscr/rjaf423 | PMID 40585923 Get It

Abstract Acute appendicitis is a common surgical emergency, most often caused by luminal obstruction from fecaliths. Rarely, foreign body ingestion can lead to appendicitis, particularly when small objects like lead shot become lodged in the appendix. We present the case of a 30-year-old man with chronic intermittent right lower quadrant pain who presented with an acute exacerbation. Imaging revealed two metallic densities in the appendix without overt signs of inflammation. He underwent laparoscopic appendectomy, which confirmed the presence of two retained lead pellets and histologic evidence of acute appendicitis. The patient had a history of frequent game meat consumption. This case underscores a rare but important etiology of appendicitis and the potential for systemic lead exposure from retained foreign bodies. In patients with relevant social histories and suggestive imaging, clinicians should consider this diagnosis and proceed with timely surgical management to prevent complications.
Global genetic prevalence estimates of primary hyperoxaluria are greater than previously reported
Rumsby, Gill , Cogal, Andrea G. , Glover, Michelle, Harris, Peter C. , Harris, Peter C , Mandrile, Giorgia , Sciannameo, Veronica , Lieske, John C.

Clinical Kidney Journal | June 27, 2025 | Volume: 18 | Issue: 7 | Pages: No page available

10.1093/ckj/sfaf194 | PMID 40873808 Get It

ABSTRACT Background Primary hyperoxaluria (PH), a rare autosomal recessive disease of oxalate accumulation in the kidneys, is caused by biallelic pathogenic changes in three known genes: AGXT (PH1), GRHPR (PH2) and HOGA1 (PH3). Methods To better understand the overall risk of developing clinical PH, we manually curated and classified PH genetic variants and calculated the estimated genetic prevalence overall and in five ethnic subpopulations using allelic frequencies from the population Genome Aggregation Database (gnomAD version 2.1.1). Results Of the 651 identified PH variants, 273 were found in gnomAD 2.1.1 on the day of download and after reclassification, 208 were determined pathogenic (P) or likely pathogenic (LP) (AGXT, n = 94; GRHPR, n = 46; and HOGA1, n = 68) and a further 65 were classified as rare variants of uncertain significance (VUS). Using P and LP only, estimated carrier frequency was 1:229 for PH1, 1:465 for PH2 and 1:151 for PH3, while genetic prevalence was 1:209 357 for PH1, 1:863 028 for PH2 and 1:90 834 for PH3 (i.e. nearly 5, 1 and 11 per 1 million individuals, respectively). The highest carrier frequencies for AGXT pathogenic variants were in East Asians (1 in 146) and the European non-Finnish population (1 in 187); for GRHPR, South Asians (1 in 313) and the European non-Finnish population (1 in 413); and for HOGA1, Ashkenazi Jewish (1 in 38) and East Asians (1 in 100). The estimated risk of developing PH was ≈1:59 017. Conclusions This careful benchmarking exercise indicates that a significant number of individuals at risk for PH symptoms remain undiagnosed. Since these numbers exceed known diagnosed cases of PH, improved screening and diagnosis of this underestimated disease is necessary.
Patients With Crohn’s Disease and Terminal Ileum Resection are at Increased Risk of Colorectal Cancer: A Population-Based Study
Mikhail, Inas , Ta’ani, Omar Al , Aburumman, Razan , Alsakarneh, Saqr, Al Ta'ani, Omar , Alsakarneh, Saqr , Farraye, Francis A. , Hashash, Jana G.

Inflammatory Bowel Diseases | June 27, 2025 | Volume: 31 | Issue: 9 | Pages: 2593-2596

10.1093/ibd/izaf118 | PMID 40577099 Get It

Abstract Patients with Crohn’s disease (CD) who undergo terminal ileum (TI) resection experience altered bile acid absorption, which may influence colorectal cancer (CRC) risk. We conducted a propensity-matched cohort study using TriNetX to compare CRC risk in patients with CD who underwent TI resection versus those who did not. Terminal ileum resection was associated with an increased risk of CRC (aHR = 2.58, 95% CI, 1.72–3.86). Patients with TI resection also had higher odds of colorectal polyps. These findings suggest the need for heightened CRC surveillance in patients with CD undergoing TI resection.
A Multiomics Study of Circulating Proteins and Kidney Stone Risk
Zhou, Le‐Ting , Stark, Isaac W. , Jayachandran, Muthuvel , Harris, Peter C. , Rule, Andrew D. , Koo, Kevin , Larson, Nicholas B. , Lieske, John C. , Larson, Nicholas B , Lieske, John C , Rule, Andrew D , Harris, Peter C , McDonnell, Shannon K.

Journal of the American Society of Nephrology | June 27, 2025 | Volume: 36 | Issue: 12 | Pages: 2456-2468

10.1681/asn.0000000768 | PMID 40577066 Get It

Key Points Circulating proteins independently associated with kidney stone diagnosis are related to kidney stone matrix. Lower circulating uromodulin and higher scavenger receptor cysteine-rich domain-containing group B protein levels were associated with higher kidney stone risk, whereas kidney stone presence elevates plasma matrix metalloproteinase 7 level. The protective effect of uromodulin against kidney stones was independent of kidney function. Background Kidney stones are increasingly recognized as a systemic disorder with a high global prevalence. However, large proteomics studies are lacking. Methods An individual-level proteomics study with rigorous adjustments was performed on 35,331 UK Biobank participants to uncover the independent associations between 2922 circulating proteins and prevalent kidney stone disease. Mendelian randomization analysis was used to assess causal relationships. Findings were validated using genomic data from the Mayo Clinic Biobank ( N =43,744), concentration-response analysis, transcriptomics analyses, and additional genome-wide association studies. Results Nine plasma proteins were independently associated with a kidney stone diagnosis, including reduced uromodulin (UMOD; β , −0.10; 95% confidence interval [CI], −0.15 to −0.05) and elevated scavenger receptor cysteine-rich domain-containing group B protein (SSC4D; β , 0.28; 95% CI, 0.17 to 0.38) and were enriched in extracellular matrix pathways. Mendelian randomization analysis revealed that the presence of kidney stone contributed to elevated levels of matrix metalloproteinase 7. Conversely, lower plasma UMOD (odds ratio [OR], 0.93; 95% CI, 0.90 to 0.97) and higher plasma SSC4D (OR, 1.10; 95% CI, 1.02 to 1.18) were associated with kidney stone risk. These associations were consistently replicated in the Mayo Clinic Biobank dataset (UMOD; OR, 0.92; 95% CI, 0.86 to 0.98; SSC4D; OR, 1.13; 95% CI, 1.01 to 1.27) and further validated by a concentration-response analysis. Single-nucleus RNA sequencing and quantitative trait loci analyses confirmed consistent associations between thick ascending limb UMOD expression and stone former status and with blood and urine UMOD concentrations. Genome-wide association study analysis, adjusted for eGFR, suggested that the protective role of UMOD against kidney stones was independent of kidney function. Conclusions This study highlights significant associations between concentrations of specific blood proteins and a history of kidney stones. Several implicated proteins are related to kidney stone matrix, with UMOD independently associated with lower risk and SSC4D with higher risk of kidney stones.
Impact of CKD/Kidney Failure on Angiodysplasia-Related Gastrointestinal Bleeding
He, Mingyue , Shah, Ankur , Wang, Yichen , Gillespie, Avrum , Shah, Ankur D , Wang, Yichen

Kidney360 | June 27, 2025 | Volume: 6 | Issue: 10 | Pages: 1689-1701

10.34067/kid.0000000901 | PMID 40577068 Get It

Key Points First US national study showing angiodysplasia-related gastrointestinal bleeding incidence and readmissions rises progressively with worsening CKD stage. Patients with kidney failure were less likely to receive endoscopy, which was linked to higher mortality, revealing a potential care gap. Recurrent angiodysplasia-related gastrointestinal bleeding was the leading cause of 30-day readmission; lack of endoscopy was an independent predictor of readmission. Background Angiodysplasia-related gastrointestinal bleeding (AGIB) is an increasingly recognized cause of hospitalization, particularly among patients with CKD. Although AGIB has been linked to kidney failure (KF), its burden across CKD stages remains unclear. This study aimed to evaluate AGIB incidence, outcomes, and readmissions across CKD stages using the largest inpatient and readmission databases in the United States. Methods We conducted a retrospective cohort study using the 2022 National Inpatient Sample and Nationwide Readmissions Database. Adult patients hospitalized with AGIB were identified and stratified into five groups: non-CKD, early CKD (stage 3), advanced CKD (stages 4–5 not on dialysis), KF (ESKD requiring chronic dialysis), and others. The primary outcome was AGIB hospitalization incidence. Secondary outcomes included in-hospital mortality, disease severity, treatment interventions, health care utilization, and 30-day readmission. Multivariable regression models were used to identify independent risk. Results In 2022, 46,670 adults were hospitalized with AGIB (0.17% of all admissions). CKD/KF was an independent risk factor for AGIB hospitalization, with risk increasing progressively with worsening kidney function (adjusted odds ratio [aOR]: 1.42 [1.34 to 1.50; early CKD], 1.89 [1.72 to 2.07; advanced CKD], 2.51 [2.32 to 2.72; KF]; all P < 0.001). The overall in-hospital mortality rate was 1.04%, higher among patients with CKD. KF was independently associated with higher mortality (aOR, 1.87 [1.06 to 3.27]), lower rates of endoscopic evaluation (aOR, 0.53 [0.43 to 0.65]), and longer hospital stays. Endoscopy was associated with lower mortality (aOR, 0.54 [0.32 to 0.92]). The 30-day all-cause readmission rate was 22.3%, with recurrent AGIB as the leading cause. Readmission risk increased progressively with CKD stage. Conclusions CKD progression is strongly associated with increased risk of AGIB hospitalization and readmission. KF and lack of endoscopic evaluation were independent mortality risk factors. These findings highlight the need for proactive management strategies in this high-risk population.
Ectopic pseudojoints in fibrodysplasia ossificans progressiva
Pignolo, Robert J. , Mukaddam, Mona Al , Morhart, Rolf, Drake, Luke T, Kneeland, Bruce , Towler, O. Will , Al Mukaddam, Mona , Broski, Stephen, Broski, Stephen M. , Kaplan, Frederick S.

JBMR Plus | June 27, 2025 | Volume: 9 | Issue: 8 | Pages: No page available

10.1093/jbmrpl/ziaf107 | PMID 40757145 Get It

Abstract Pseudoarthroses (false joints) occur as a complication of fracture healing in the normotopic skeleton but have not been reported at ectopic sites. Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by progressive heterotopic ossification (HO) and congenital skeletal abnormalities including developmental arthropathy in the normotopic skeleton. Here, we report ectopic pseudojoint formation in 6 patients with FOP, all occurring after painful flare-ups and HO in soft connective tissues of the knee, hip, and forearm. To our knowledge, FOP is the only human condition in which ectopic pseudojoint formation occurs. These findings support that dysregulated BMP pathway signaling from mutant ACVR1 mediates not only HO, but also ectopic pseudojoint formation, and that ectopic pseudojoints can arise from de novo musculoskeletal elements.
Breaking barriers: A journey towards comprehensive care and understanding for patients with sickle cell disease
Bye, Kyo , Juresic, Sanny , Rouse, Rachelle, Smith, N., Bye, Katelyn N , Smith, Nathan T. , Bye, Katelyn N

American Journal of Health-System Pharmacy | June 27, 2025 | Volume: 82 | Issue: 17 | Pages: e778-e781

10.1093/ajhp/zxaf167 | PMID 40576453 Get It

The Traumatic Brain Injury-Alzheimer’s Disease and Alzheimer’s Disease-related Dementia Caregiver Support Intervention: A Mixed Methods Evaluation of Program Feasibility, Acceptability, and Utility
Wilson, Mary Ann , Birkeland, Robyn , Albers, Elizabeth , Louwagie, Katie , Finn, Jacob A. , Ostenso, Samantha , Gaugler, Joseph E. , Chesak, Sherry S. , Gaugler, Joseph E , Wilson, Mara, Ratner, Edward R.

Innovation in Aging | June 27, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/geroni/igaf057 | PMID 40709322 Get It

Abstract Background and Objectives Research has established that unpaid family members, friends, or others who care for persons with dementia (ie, caregivers) may encounter socioemotional and physical health concerns as a consequence of providing extensive assistance. Similarly, caregivers for people living with traumatic brain injury (TBI) often experience a range of stressors and negative mental health outcomes due to care demands. Individuals with TBI often develop Alzheimer’s disease and Alzheimer’s disease-related dementia (AD/ADRD). This history of TBI may introduce complications to AD/ADRD caregiving. A comprehensive intervention grounded in the understanding of the complex caregiving context of both diagnoses is warranted to address the unique needs and concerns of TBI-AD/ADRD caregivers. Research Design and Methods This study evaluated the feasibility of the TBI-AD/ADRD Caregiver Support Intervention (TACSI) psychoeducational program, designed to support the unique subset of caregivers facing the challenge of assisting relatives with AD/ADRD and a history of TBI. TACSI, a 6-session telehealth intervention, provides tailored psychosocial and psychoeducational coaching. In partnership with the 2 national healthcare centers, 15 caregivers enrolled in the 3-month feasibility study evaluating the design and subsequent refinement of TACSI. Mixed methods data were collected from 3-month follow-up surveys and qualitative data from postintervention interviews. Results The feasibility, utility, and acceptance of TACSI were established. Caregivers liked the telehealth delivery and the personalized nature of TACSI, yet some expressed it would have been more beneficial earlier in their caregiving journey. Discussion and Implications Caregivers valued the TACSI program. Their feedback has been applied to improve TACSI content and delivery for a larger pilot randomized controlled trial that is currently underway.